Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
qfHGtkRLhA8BJ8bD
